Browsing Category
Featured Articles
Lilly Files Six Lawsuits Against Black-Market Retatrutide Sellers
Eli Lilly and Company has filed six new lawsuits against U.S. entities accused of selling unauthorized retatrutide products, escalating the pharmaceutical company's efforts to combat…
Read More...
Read More...
Sobi Partners With Innate Pharma on Lacutamab in T-Cell Lymphoma
Swedish pharmaceutical company Sobi and Innate Pharma have entered into a strategic partnership to advance lacutamab, an investigational treatment for cutaneous T-cell lymphoma (CTCL),…
Read More...
Read More...
Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo
Pfizer has reported positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) in patients with nonsegmental vitiligo (NSV), supporting the company’s plans to…
Read More...
Read More...
AbCellera, Vertex Partner on T-Cell Engagers for Autoimmune Diseases
AbCellera and Vertex Pharmaceuticals have entered into a collaboration to research, develop, manufacture and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases…
Read More...
Read More...
argenx to Acquire Forte Biosciences in $2.2 Billion Deal
argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion in cash, strengthening its immunology pipeline with a promising experimental therapy for autoimmune…
Read More...
Read More...
Pfizer, Eisai Partner to Co-Promote Nurtec in Japan
Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning…
Read More...
Read More...
FDA Grants Fast Track Status to Lundbeck’s Narcolepsy Drug
Lundbeck has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Lu AH69593, its investigational oral orexin 2 receptor agonist being developed to treat…
Read More...
Read More...
FDA Approves GSK’s Jideytro for ROS1-Positive Lung Cancer
GSK has received U.S. Food and Drug Administration (FDA) approval for Jideytro (zidesamtinib), a next-generation targeted therapy for adults with locally advanced or metastatic…
Read More...
Read More...
Bristol Myers Squibb Expands AI Supercomputer for Drug Discovery
Bristol Myers Squibb (BMS) is significantly expanding its artificial intelligence capabilities with the deployment of a second NVIDIA DGX SuperPOD, strengthening its efforts to…
Read More...
Read More...
Novo Nordisk Sues Lilly Over Obesity Drug Advertising Claims
Novo Nordisk has filed a lawsuit against Eli Lilly and Company and Lilly USA in the United States, alleging that the pharmaceutical giant's advertising for its blockbuster diabetes and…
Read More...
Read More...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA (enlicitide) 20 mg tablets for adults…
Read More...
Read More...
FDA Grants Full Approval to Fabhalta for IgA Nephropathy
Novartis has announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for adults with primary immunoglobulin A nephropathy…
Read More...
Read More...
EU Approves Wegovy Pill for Obesity Treatment
Novo Nordisk has announced that the European Commission (EC) has approved Wegovy® pill (oral semaglutide 25 mg) for the treatment of adults living with obesity or overweight with at…
Read More...
Read More...
Teva Secures Global Rights to Polpharma’s Ocrevus Biosimilar
Teva Pharmaceuticals International GmbH has entered into a global licensing agreement with Polpharma Biologics International AG for exclusive commercialization rights to Polpharma…
Read More...
Read More...
Bayer Launches Clinical Trials Alliance With Colorado Health Partners
Bayer has formed a strategic clinical trials alliance with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, marking the company’s first collaboration of…
Read More...
Read More...
Ipsen Acquires Memo Therapeutics to Advance BK Virus Treatment
Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...
Read More...
EU Approves Novartis’ Itvisma for Broad SMA Patient Population
Novartis has received European Commission approval for Itvisma® (onasemnogene abeparvovec), expanding access to gene replacement therapy for children, teenagers and adults living with…
Read More...
Read More...
Sanofi’s Nexviazyme Shows Positive Phase 3 Results in Infantile Pompe Diseas
Sanofi has reported positive Phase 3 results for Nexviazyme, also known as avalglucosidase alfa, in infants with infantile-onset Pompe disease, a rare and life-threatening genetic…
Read More...
Read More...
Merck to Acquire Bio-Techne in $11.3 Billion Deal
Merck KGaA, Darmstadt, Germany, has announced a definitive agreement to acquire U.S.-based life sciences company Bio-Techne Corporation in an all-cash transaction valued at…
Read More...
Read More...
Ionis, Recordati Partner to Expand Zilganersen Access Globally
Ionis Partners with Recordati to Commercialize Alexander Disease Therapy Outside U.S.
Ionis Pharmaceuticals has entered into a strategic licensing agreement with Recordati to expand…
Read More...
Read More...
